Abstract:DNA damage repair (DDR) genes are involved in developing breast cancer. Recently, a targeted therapeutic strategy through DNA repair machinery, including PARPi, has initially shown broad development and application prospects in breast cancer therapy. However, few studies that focused on the correlation between the expression level of DNA repair genes, prognosis, and immune response in breast cancer patients have been recently conducted. Herein, we focused on identifying differentially expressed DNA repair genes (DEGs) in breast cancer specimens and normal samples using the Wilcoxon rank-sum test. Biofunction enrichment analysis was performed with DEGs using the R software "cluster Profiler" package. DNA repair genes were involved in multivariate and univariate Cox regression analyses. After the optimization by AIC value, 11 DNA repair genes were sorted as prognostic DNA repair genes for breast cancer patients to calculate risk scores. Simultaneously, a nomogram was used to represent the prognostic model, which was validated using a calibration curve and C-index. Single-sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithms, and ESTIMATE scores were applied to evaluate the immune filtration of tumor samples. Subsequently, anticarcinogen sensitivity analysis was performed using the R software "pRRophetic" package. Unsupervised clustering was used to excavate the correlation between the expression level of prognostic-significant DNA repair genes and clinical features. In summary, 56 DEGs were sorted, and their potential enriched biofunction pathways were revealed. In total, 11 DNA repair genes (UBE2A, RBBP8, RAD50 , FAAP20, RPA3, ENDOV, DDB2, UBE2V2, MRE11 , RRM2B, and PARP3 ) were preserved as prognostic genes to estimate risk score, which was applied to establish the prognostic model and stratified breast cancer patients into two groups with high or low risk. The calibration curve and C-index indicated that they reliably predicted the survival of breast cancer patients. Immune filtration analysis, anticarcinogen sensitivity analysis, and unsupervised clustering were applied to reveal the character of DNA repair genes between low- and high-risk groups. We identified 11 prognosis-significant DNA repair genes to establish prediction models and immune responses in breast cancer patients.

Genetic and Functional Studies of Genes That Regulate DNA-Damage-Induced Cell Death

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management

Functional Analysis of BARD1 Missense Variants on Homology‐Directed Repair in Ovarian and Breast Cancers

LARP7 is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

Construction of a DNA Damage Repair Gene Signature for Predicting Prognosis and Immune Response in Breast Cancer.

A Synergetic Effect of BARD1 Mutations on Tumorigenesis

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient

Integrated pan-cancer analysis and experimental verification of the roles of meiotic nuclear divisions 1 in breast cancer

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Bioinformatics Analysis of Expression and Alterations of BARD1 in Breast Cancer.

Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer.

Synergistic Effects of Anlotinib and DDP on Breast Cancer: Targeting the VEGF/JAK2/STAT3 Axis

Synergistic Effects of Anlotinib and DDP Synergy in Breast Cancer Treatment: Inhibiting of Cell Growth and Migration, and Augmenting Apoptosis and Autophagy Via Modulation of the VEGF/JAK2/STAT3 Axis

Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

BRCA1: Cell Cycle Checkpoint, Genetic Instability, DNA Damage Response and Cancer Evolution

Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

Chemical Inductors of Proximity Associating DNA Damage-Binding Protein 2 and XIAP as Targeted Therapy for General Cancers

Brca1-Associated Proteins: Novel Targets For Breast Cancer Radiation Therapy

Comprehensive Analysis of DNA Damage Repair Genes and Identification of RAD54L as an Immunological and Prognostic Biomarker in Clear Cell Renal Cell Carcinoma and Other Cancers